Manufacture and testing of zika virus or zika-related virus vaccine products
Ended Awarded Last action
- Contract number
- HHSN26100048
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $14,640,019
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $14,640,019.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Economy Act FAR subpart 17.5
- National interest action
- Coronavirus COVID-19
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $14,640,019 |
About this award
This is a $14,640,019.00 cost-plus-fixed-fee delivery order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Leidos Biomedical Research Inc. to manufacture and test Zika virus or Zika-related virus vaccine products. The contract is not set aside. Leidos Biomedical Research, a subsidiary of Leidos Holdings Inc., has a history of supporting federal biomedical research programs at organizations like the NIH. The prime contractor has subcontracted a portion of the work to Texcell-North America, Inc. to perform viral clearance evaluation studies in support of the vaccine development effort. This contract supports national interest related to the Coronavirus COVID-19 pandemic.
Quick answers
Who was awarded contract HHSN26100048?
HHSN26100048 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 20, 2017.
How much is contract HHSN26100048 worth?
The government has obligated $14,640,019 on HHSN26100048.
Which agency awarded contract HHSN26100048?
National Cancer Institute (National Institutes of Health) awarded HHSN26100048, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract HHSN26100048 an order under another contract?
Yes. HHSN26100048 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100048 competed?
The extent of competition for HHSN26100048 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award